Researchers from big pharma, academia, and proteomics equipment suppliers at last week’s ACI (Active Communications International) proteomics meeting in Boston, chaired by Steven Naylor, chief technology officer at Beyond Genomics, got a look at a broad sampling of the various approaches to applying proteomics to drug discovery. In fact, the only thing missing was a talk from a HUPO representative touting the advantages of large-scale proteomics projects.